Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risevistinel in PTSD
NCT05181995Phase 3Terminated
- Sponsor
- Aptinyx Inc.
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Aptinyx Inc. Primary endpoint: Clinician-Administered PTSD Scale for the DSM-5 at 10 weeks. Started Dec 2021; status: terminated.
02
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05181995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181995.